Connect with us

Impact Investing

M2TEST Launches Crowdfunding for the New BES TEST Technology for Bone Fragility

SME M2TEST pioneers BES TEST, a bone fragility prevention technology surpassing MOC in accuracy and invasiveness. With over 12,000 patients and endorsements from medical institutions, it exceeded its equity crowdfunding goal of €100,000. BES TEST’s SAAS model reduces radiation exposure, predicts fractures, and targets markets beyond osteoporosis, aiming for global expansion.




The innovative SME M2TEST, which operates in the Trieste science park, has developed a technology to prevent bone fragility, which is more accurate and less invasive than the standard MOC method for densitometric diagnosis.

It is called BES TEST, it allows an in-depth examination to evaluate the elasticity of the bone structure and is already used by 16 early adopters, including the Maugeri Foundation, Verona Hospital, Studio Igea, and CRG and more than 12,000 patients

To consolidate its position on the Italian and European markets and land on the US market,M2TEST has relied on equity crowdfunding with an ongoing campaign on CrowdFundMe which has already exceeded the first economic target of 100,000 euros.

A more accurate and less invasive test

The technology is marketed to doctors and clinics as SAAS (software as a service) and allows them to complete diagnoses with less radiation exposure and prevent fragility and stress fractures, while simultaneously cutting healthcare costs.

The accuracy of the diagnosis through the BES TEST can reach 90% (compared to 50% for MOC) and can also identify subjects at risk who escape the classic densitometric diagnosis, providing a complete and correct analysis, both in the presence of primary (physiological) osteoporosis , or secondary or caused by very frequent pathologies (tumors, celiac disease, diabetes, kidney diseases etc.), or by the use of certain drugs (hormonal therapies, corticosteroids, some antacids).

Compared to traditional methods, the new BES test also and above all evaluates the internal structure of the bone and not just the density and this is one of its main strengths.

The objectives of M2TEST

M2TEST aims to become the new reference standard for fragility fractures and its technology also finds application in the sectors of sport, nephrology, oncology and space missions.

In particular, the company aims to reach fifty hospitals in Italy and one hundred private clinics by the end of 2024 and expects to reach a turnover of 2 million euros in 2025, with a positive Ebitda starting from next year.

The equity crowdfunding campaign on CrowdFundMe is aimed at the opening of a US office, expansion in Italy and Europe, new hires and technological investments.

“ Given that our company aims to improve the lives of people, of all people, it seemed logical to us to open up to everyone the possibility of investing and participating in our growth, of giving themselves a gift by purchasing a share, even a small one, of a revolutionary startup that can do the good of everyone,” declared the CEO and co-founder, Alessandra Nicolosi .

Who is M2TEST

M2TEST, whose headquarters are located in the Trieste Science Park, boasts a team with decades of experience in the bio-engineering sector, including Francesca Cosmi, Professor at the University of Trieste with study periods at Berkeley and NASA, and Alessandra Nicolosi , who has participated in numerous national and international accelerators (e.g. Skydeck-Berkeley).

To date, M2TEST has obtained three patents and refers to two highly promising markets: digital health, whose global value stood at $233.5 billion in 2022 and is estimated to reach $981.5 billion in 2032 and digital radiology: $4.4 billion by 2028.


(Featured image by planet_fox via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us

Jeremy Whannell loves writing about the great outdoors, business ventures and tech giants, cryptocurrencies, marijuana stocks, and other investment topics. His proficiency in internet culture rivals his obsession with artificial intelligence and gaming developments. A biker and nature enthusiast, he prefers working and writing out in the wild over an afternoon in a coffee shop.